File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma

TitlePreliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma
Authors
KeywordsDose escalation
IMRT
Nasopharyngeal carcinoma
Issue Date2006
PublisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobp
Citation
International Journal of Radiation Oncology - Biology - Physics, 2006, v. 64 n. 2, p. 374-381 How to Cite?
AbstractPurpose: To study the safety and efficacy of dose escalation in tumor for locally advanced nasopharyngeal carcinoma (NPC). Methods and Materials: From September 2000 to June 2004, 50 patients with T3-T4 NPC were treated with intensity-modulated radiotherapy (IMRT). Fourteen patients had Stage III and 36 patients had Stage IVA-IVB disease. The prescribed dose was 76 Gy to gross tumor volume (GTV), 70 Gy to planning target volume (PTV), and 72 Gy to enlarged neck nodes (GTVn). All doses were given in 35 fractions over 7 weeks. Thirty-four patients also had concurrent cisplatin and induction or adjuvant PF (cisplatin and 5-fluorouracil). Results: The average mean dose achieved in GTV, GTVn, and PTV were 79.5 Gy, 75.3 Gy, and 74.6 Gy, respectively. The median follow-up was 25 months, with 4 recurrences: 2 locoregional and 2 distant failures. All patients with recurrence had IMRT alone without chemotherapy. The 2-year locoregional control rate, distant metastases-free and disease-free survivals were 95.7%, 94.2%, and 93.1%, respectively. One treatment-related death caused by adjuvant chemotherapy occurred. The 2-year overall survival was 92.1%. Conclusions: Dose escalation to 76 Gy in tumor is feasible with T3-T4 NPC and can be combined with chemotherapy. Initial results showed good local control and survival. © 2006 Elsevier Inc.
Persistent Identifierhttp://hdl.handle.net/10722/150799
ISSN
2015 Impact Factor: 4.495
2015 SCImago Journal Rankings: 2.274
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorLeung, LHTen_HK
dc.contributor.authorCheng, ACKen_HK
dc.contributor.authorNg, WMen_HK
dc.contributor.authorKwong, PWKen_HK
dc.contributor.authorLui, WMen_HK
dc.contributor.authorYau, CCen_HK
dc.contributor.authorWu, PMen_HK
dc.contributor.authorWei, Wen_HK
dc.contributor.authorAu, Gen_HK
dc.date.accessioned2012-06-26T06:10:40Z-
dc.date.available2012-06-26T06:10:40Z-
dc.date.issued2006en_HK
dc.identifier.citationInternational Journal of Radiation Oncology - Biology - Physics, 2006, v. 64 n. 2, p. 374-381en_HK
dc.identifier.issn0360-3016en_HK
dc.identifier.urihttp://hdl.handle.net/10722/150799-
dc.description.abstractPurpose: To study the safety and efficacy of dose escalation in tumor for locally advanced nasopharyngeal carcinoma (NPC). Methods and Materials: From September 2000 to June 2004, 50 patients with T3-T4 NPC were treated with intensity-modulated radiotherapy (IMRT). Fourteen patients had Stage III and 36 patients had Stage IVA-IVB disease. The prescribed dose was 76 Gy to gross tumor volume (GTV), 70 Gy to planning target volume (PTV), and 72 Gy to enlarged neck nodes (GTVn). All doses were given in 35 fractions over 7 weeks. Thirty-four patients also had concurrent cisplatin and induction or adjuvant PF (cisplatin and 5-fluorouracil). Results: The average mean dose achieved in GTV, GTVn, and PTV were 79.5 Gy, 75.3 Gy, and 74.6 Gy, respectively. The median follow-up was 25 months, with 4 recurrences: 2 locoregional and 2 distant failures. All patients with recurrence had IMRT alone without chemotherapy. The 2-year locoregional control rate, distant metastases-free and disease-free survivals were 95.7%, 94.2%, and 93.1%, respectively. One treatment-related death caused by adjuvant chemotherapy occurred. The 2-year overall survival was 92.1%. Conclusions: Dose escalation to 76 Gy in tumor is feasible with T3-T4 NPC and can be combined with chemotherapy. Initial results showed good local control and survival. © 2006 Elsevier Inc.en_HK
dc.languageengen_US
dc.publisherElsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/ijrobpen_HK
dc.relation.ispartofInternational Journal of Radiation Oncology - Biology - Physicsen_HK
dc.subjectDose escalationen_HK
dc.subjectIMRTen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols - Therapeutic Useen_US
dc.subject.meshCarcinoma - Pathology - Radiotherapyen_US
dc.subject.meshCisplatin - Administration & Dosageen_US
dc.subject.meshCombined Modality Therapyen_US
dc.subject.meshDose Fractionationen_US
dc.subject.meshFemaleen_US
dc.subject.meshFluorouracil - Administration & Dosageen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNasopharyngeal Neoplasms - Pathology - Radiotherapyen_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshRadiation Injuries - Complicationsen_US
dc.subject.meshRadiotherapy, Intensity-Modulated - Methodsen_US
dc.subject.meshStomatitis - Etiologyen_US
dc.subject.meshSurvival Analysisen_US
dc.titlePreliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailKwong, DLW: dlwkwong@hku.hken_HK
dc.identifier.emailWei, W: hrmswwi@hku.hken_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.identifier.authorityWei, W=rp00323en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.ijrobp.2005.07.968en_HK
dc.identifier.pmid16213105-
dc.identifier.scopuseid_2-s2.0-30544442262en_HK
dc.identifier.hkuros137513-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-30544442262&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume64en_HK
dc.identifier.issue2en_HK
dc.identifier.spage374en_HK
dc.identifier.epage381en_HK
dc.identifier.isiWOS:000234883300005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridKwong, DLW=15744231600en_HK
dc.identifier.scopusauthoridSham, JST=24472255400en_HK
dc.identifier.scopusauthoridLeung, LHT=7202048113en_HK
dc.identifier.scopusauthoridCheng, ACK=36055097300en_HK
dc.identifier.scopusauthoridNg, WM=7401613513en_HK
dc.identifier.scopusauthoridKwong, PWK=7006992418en_HK
dc.identifier.scopusauthoridLui, WM=7101851125en_HK
dc.identifier.scopusauthoridYau, CC=7007038422en_HK
dc.identifier.scopusauthoridWu, PM=8663653900en_HK
dc.identifier.scopusauthoridWei, W=7403321552en_HK
dc.identifier.scopusauthoridAu, G=7003748615en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats